JP2003510329A5 - - Google Patents

Download PDF

Info

Publication number
JP2003510329A5
JP2003510329A5 JP2001526545A JP2001526545A JP2003510329A5 JP 2003510329 A5 JP2003510329 A5 JP 2003510329A5 JP 2001526545 A JP2001526545 A JP 2001526545A JP 2001526545 A JP2001526545 A JP 2001526545A JP 2003510329 A5 JP2003510329 A5 JP 2003510329A5
Authority
JP
Japan
Prior art keywords
acid
rapamycin
carbons
silyl ether
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001526545A
Other languages
English (en)
Japanese (ja)
Other versions
JP4289813B2 (ja
JP2003510329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/026445 external-priority patent/WO2001023395A2/en
Publication of JP2003510329A publication Critical patent/JP2003510329A/ja
Publication of JP2003510329A5 publication Critical patent/JP2003510329A5/ja
Application granted granted Critical
Publication of JP4289813B2 publication Critical patent/JP4289813B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001526545A 1999-09-29 2000-09-27 ラパマイシン誘導体のレギオ選択的な合成 Expired - Fee Related JP4289813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40883099A 1999-09-29 1999-09-29
US09/408,830 1999-09-29
PCT/US2000/026445 WO2001023395A2 (en) 1999-09-29 2000-09-27 Regioselective synthesis of rapamycin derivatives

Publications (3)

Publication Number Publication Date
JP2003510329A JP2003510329A (ja) 2003-03-18
JP2003510329A5 true JP2003510329A5 (enExample) 2008-02-21
JP4289813B2 JP4289813B2 (ja) 2009-07-01

Family

ID=23617953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001526545A Expired - Fee Related JP4289813B2 (ja) 1999-09-29 2000-09-27 ラパマイシン誘導体のレギオ選択的な合成

Country Status (24)

Country Link
EP (1) EP1216251B1 (enExample)
JP (1) JP4289813B2 (enExample)
KR (1) KR100754236B1 (enExample)
CN (1) CN1176925C (enExample)
AR (1) AR029181A1 (enExample)
AT (1) ATE233269T1 (enExample)
AU (1) AU782234B2 (enExample)
BR (1) BR0014433A (enExample)
CA (1) CA2385461C (enExample)
CZ (1) CZ300368B6 (enExample)
DE (1) DE60001510T2 (enExample)
DK (1) DK1216251T3 (enExample)
EA (1) EA004331B1 (enExample)
ES (1) ES2189768T3 (enExample)
HK (1) HK1044774B (enExample)
HU (1) HUP0202609A3 (enExample)
IL (2) IL148542A0 (enExample)
MX (1) MXPA02003243A (enExample)
NO (1) NO20021360L (enExample)
NZ (1) NZ517644A (enExample)
PL (1) PL200899B1 (enExample)
TW (1) TWI256395B (enExample)
WO (1) WO2001023395A2 (enExample)
ZA (1) ZA200201918B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
EP1737869A1 (en) * 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
CA2564811A1 (en) 2004-04-14 2005-10-27 Wyeth Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
SV2006002188A (es) 2004-08-10 2006-03-15 Wyeth Corp Derivados de cci - 779 y metodos para su preparacion ref. am-101759salvo
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP1856130A1 (en) 2005-02-09 2007-11-21 Wyeth a Corporation of the State of Delaware Cci-779 polymorph and use thereof
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
AU2011210227A1 (en) * 2010-01-28 2012-08-30 Fresenius Kabi Oncology Ltd. Process for the preparation of Temsirolimus and its intermediates
CN102020662B (zh) 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔制备方法
EP2694520A1 (en) * 2011-04-01 2014-02-12 Sandoz AG Regioselective acylation of rapamycin at the c-42 position
CN103421023B (zh) * 2013-07-30 2015-09-23 福建省微生物研究所 一种替西罗莫司的合成工艺
CN104086564B (zh) * 2014-07-30 2019-02-05 江苏奥赛康药业股份有限公司 一种高纯度坦罗莫司的制备方法
CN106146536B (zh) * 2015-04-25 2019-07-26 山东新时代药业有限公司 一种依维莫司的制备方法
CA3017690C (en) * 2016-03-14 2024-02-20 Wisconsin Alumni Research Foundation Oligolactic acid conjugates and micelles with enhanced anticancer efficacy
CN107561170B (zh) * 2016-07-02 2021-07-30 山东新时代药业有限公司 一种坦西莫司中间体的分析检测方法
CN108948046B (zh) * 2017-05-20 2020-11-10 鲁南制药集团股份有限公司 一种替西罗莫司的中间体及其制备方法
CN108948045A (zh) * 2017-05-20 2018-12-07 鲁南制药集团股份有限公司 一种替西罗莫司的制备方法
CN109206441B (zh) * 2017-06-30 2022-05-20 正大天晴药业集团股份有限公司 一种依维莫司的纯化方法
CN109776570A (zh) * 2017-11-14 2019-05-21 上海医药工业研究院 一种依维莫司中间体、其制备方法及其应用
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
CN109369679A (zh) * 2018-12-24 2019-02-22 江苏卓和药业有限公司 一种雷帕霉素的精制方法
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
BR112022010754A2 (pt) 2019-12-05 2022-08-23 Anakuria Therapeutics Inc Análogos de rapamicina e usos dos mesmos
CN113372359A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种坦西莫司的制备方法
CN114106014B (zh) * 2020-08-27 2024-03-15 鲁南制药集团股份有限公司 一种依维莫司的制备方法
CN115028658A (zh) * 2022-07-06 2022-09-09 国药集团川抗制药有限公司 雷帕霉素硅醇酯及其制备方法和应用
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines

Similar Documents

Publication Publication Date Title
JP4289813B2 (ja) ラパマイシン誘導体のレギオ選択的な合成
US6277983B1 (en) Regioselective synthesis of rapamycin derivatives
JPH0578377A (ja) ラパマイシンのシリルエーテル類
DE69624921T2 (de) Rapamycinderivate
JP2018150331A5 (enExample)
JP5117390B2 (ja) メイタンシノールの調製法
JP2015517402A5 (enExample)
KR950703567A (ko) O-알킬화된 라파미신 유도체 및 면역 억제제로서의 용도 (o-alkylated rapamycin derivatives and their use, particularly as immuno-suppressants)
JP2008542214A5 (enExample)
JP2018528244A5 (enExample)
JP2013136631A5 (enExample)
JP2019516720A5 (enExample)
JP2006528667A5 (enExample)
RU2008134424A (ru) Способ получения производных рапамицина
JP2007519685A5 (enExample)
DE102007055341A1 (de) Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
ATE535538T1 (de) Verfahren zur herstellung von guggulsteronen und guggulsterol
JP2010530379A5 (enExample)
JP2006523223A5 (enExample)
RU2007118654A (ru) Способ этерификации тиокарбоновой кислоты
WO2006063757A3 (de) Wasserfreie metalloxidkolloide und metalloxidpolymere, verfahren zu deren herstellung und verwendung
RU2022101085A (ru) Антагонист нейрокинина-1
JP2002511470A (ja) カルバペネム中間体のチタン触媒による製造